Ostrava hosted the 16th annual International Myeloma and Cell Therapy workshop

The two-day workshop consisted of a total of 21 lectures (by 17 foreign and 4 Czech speakers), which were also streamed online to all the interested audience worldwide. The speakers presented diverse topics covering a wide range of myeloma issues – from basic research, through diagnostic methods, to the possibilities and limitations of therapy.
Among the other topics covered during the workshop, special attention was given to the issues of the tumor microenvironment and intercellular interactions that play an important role in the pathogenesis of this disease. The first-class research in this area was presented by, among others, prof. Tom Cupedo (Erasmus MC Rotterdam), prof. Eline Menu (VUB Brussels), and Dr. Cirino Botta (University of Palermo).

The second part of the workshop was focused on cell therapy which is currently one of the most modern approaches in cancer treatment. The experience in the use of therapeutic CAR – T cells was presented by prof. Michael Hudecek (University of Wüzburg), Dr. Piotr Celichowski (Blood Cancer Research Group, Ostrava), or Dr. Michal Šmída (CEITEC, Brno).
Prof. Michael O'Dwyer (National University of Ireland) presented the current role of NK cells in myeloma therapy.
Dr. Leo Rasche (University of Wüzburg) drew attention to the issue of tumor diversity affecting the effectiveness of immunotherapy.

A special section of the event belonged to the top hemato-oncologist and professor at Harvard University - Dr. Kenetth C. Anderson (Dana-Farber Cancer Insitute), who gave a talk on the latest available treatment options for multiple myeloma.

The organizers believe that the next Workshop will attract an even larger number of listeners and lecturers, especially from the Czech Republic.

The workshop was financially supported by the OP RDE project New Directions of Biomedical Research in the Ostrava Region, reg. No. CZ.02.1.01 / 0.0 / 0.0 / 18_069 / 0010060.

22.10.2021

• 
  Opening remarks - Roman Hájek and Michal Šimiček
• 
  Opening remarks - Roman Hájek and Michal Šimiček
• 
  Opening remarks - Roman Hájek and Michal Šimiček
• 
  SESSION I chair: Tereza Ševčíková
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Q&A SESSION I
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Q&A SESSION I
• 
  Da Via` Matteo Claudio, University of Milan, Italy
• 
  Q&A SESSION I
• 
  SESSION I
• 
  SESSION I
• 
  Bruno Paiva, Center for Applied Medical Research, Spain
• 
  Bruno Paiva, Center for Applied Medical Research, Spain
• 
  Q&A SESSION I
• 
  Despina Bazou, Mater Misericordiae University Hospital, Ireland
• 
  MCTW21
• 
  Q&A SESSION I
• 
  Q&A SESSION I
• 
  MCTW21
• 
  MCTW21
• 
  MCTW21
• 
  MCTW21
• 
  MCTW21
• 
  MCTW21
• 
  SESSION II chair: Zuzana Chyra
• 
  Tom Cupedo, Erasmus MC Rotterdam, Netherlands
• 
  Tom Cupedo, Erasmus MC Rotterdam, Netherlands
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  Eline Menu, VUB Brussels, Belgium
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  Cirino Botta, University of Palermo, Italy
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  Q&A SESSION II
• 
  SESSION III chair: Tomáš Jelínek
• 
  Tereza Sevcikova, Blood Cancer Research Group, Czech Republic
• 
  Tereza Sevcikova, Blood Cancer Research Group, Czech Republic
• 
  Q&A SESSION III
• 
  Q&A SESSION III
• 
  Luciano Costa - University of Alabama at Birmingham
• 
  Q&A SESSION III
• 
  MCTW21
• 
  Francesco Maura, Sylvester Comprehensive Cancer Center, University of Miami, USA
• 
  MCTW21
• 
  Morie Gertz, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
• 
  Q&A SESSION III
• 
  MCTW21
• 
  MCTW21
• 
  SESSION IV chair: Michal Šimíček
• 
  Caroline Heckman, Institute for Molecular Medicine Finland, Finland
• 
  Caroline Heckman, Institute for Molecular Medicine Finland, Finland
• 
  Q&A SESSION IV
• 
  Q&A SESSION IV
• 
  Tomas Jelinek, Blood Cancer Research Group, Ostrava, Czech Republic
• 
  Tomas Jelinek, Blood Cancer Research Group, Ostrava, Czech Republic
• 
  MCTW21
• 
  MCTW21
• 
  MCTW21
• 
  Q&A SESSION IV
• 
  Marcello Turi, Blood Cancer Research Group, Czech Republic
• 
  Marcello Turi, Blood Cancer Research Group, Czech Republic
• 
  Q&A SESSION IV
• 
  SESSION V chair: Hana Šahinbegović
• 
  Michael Hudecek, University of Würzburg, Germany
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Monika Holubová, Fakultní nemocnice Plzeň, , Czech Republic
• 
  Monika Holubová, Fakultní nemocnice Plzeň, , Czech Republic
• 
  Q&A SESSION V
• 
  Leo Rasche, Universty of Würzburg, Germany
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  MCTW21
• 
  Sophia Adamia, Dana-Farber Cancer Institute, USA
• 
  Q&A SESSION V
• 
  Q&A SESSION V
• 
  Kenneth Anderson, Dana-Farber Cancer Institute, USA
• 
  SPECIAL SESSION chair: Michal Šimíček
• 
  Q&A SPECIAL SESSION
• 
  Q&A SPECIAL SESSION
• 
  Q&A SPECIAL SESSION
• 
  Q&A SPECIAL SESSION
• 
  Q&A SPECIAL SESSION
• 
  SESSION VI chair: Matouš Hrdinka
• 
  Michal Smida, Citec, Czech Republic
• 
  Michal Smida, Citec, Czech Republic
• 
  Q&A SESSION VI
• 
  Q&A SESSION VI
• 
  Q&A SESSION VI
• 
  Piotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic
• 
  Piotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic
• 
  Piotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic
• 
  Q&A SESSION VI
• 
  Q&A SESSION VI
• 
  Michael O`Dwyer, National University of Ireland, Ireland
• 
  Closing remarks

Back